Molecularly-Targeted Strategy and NF-κB in Lymphoid Malignancies
-
- Horie Ryouichi
- Department of Hematology, School of Medicine, Kitasato University
Bibliographic Information
- Other Title
-
- Molecularly-Targeted Strategy and NF-^|^kappa;B in Lymphoid Malignancies
Search this article
Description
Molecularly-targeted therapy is a promising strategy for the treatment of cancer. Nuclear factor (NF)-κB is a transcription factor that is constitutively activated in various lymphoid malignancies and may therefore be a good therapeutic target. Lymphoid malignancies arise from different stages of normal lymphocyte differentiation and acquire distinct pathways for constitutive NF-κB activation. However, no NF-κB inhibitor has yet been successfully applied in clinical medicine. This review focuses on the concept of molecularly-targeted therapeutics with small molecule drugs, molecular mechanisms of constitutive NF-κB activation in lymphoid malignancies, and the development of NF-κB inhibitors. A future perspective regarding the development of NF-κB inhibitors is also included. [J Clin Exp Hematop 53(3) : 185-195, 2013]
Journal
-
- Journal of Clinical and Experimental Hematopathology
-
Journal of Clinical and Experimental Hematopathology 53 (3), 185-195, 2013
The Japanese Society for Lymphoreticular Tissue Research